Skip to main content

Table 1 Baseline clinical and laboratory characteristics of the study patients according to sST2 levels

From: Prognostic value of soluble suppression of tumorigenesis-2 (sST2) for cardiovascular events in coronary artery disease patients with and without diabetes mellitus

  Total n = 3641 sST2 (< 19 ng/mL) (n = 1818) sST2 (≥ 19 ng/mL) (n = 1823)
(n = 1823)
p value for trend
Age, years 61.40 (26–95) 61.03 (26–93) 61.86 (30–95) 0.031
Male, n% 2632 (72.29) 1226 (67.44) 1406 (77.13) 0.000
BMI (kg/m2) 25.64 (13.30–42.19) 25.70 (13.30–42.19) 25.60 (14.50–39.70) 0.230
Risk factors for atherosclerosis     
 Current smokers, n (%) 1668 (45.81) 810 (44.55) 858 (47.07) 0.086
 Hypertension, n (%) 2370 (65.09) 1160 (63.80) 1210 (66.37) 0.090
 Hyperlipidemia, n (%) 1120 (30.76) 581 (31.96) 539 (29.57) 0.099
 Diabetes mellitus, n (%) 1163 (31.94) 590 (32.45) 573 (31.43) 0.943
Cardiac history     
 Previous MI, n (%) 254 (6.98) 125 (6.88) 129 (7.08) 0.085
 Previous PCI/CABG, n (%) 299 (8.21) 127 (6.99) 172 (9.43) 0.003
Laboratory data     
 TC (mmol/L) 4.03 ± 1.08 4.03 ± 1.07 4.03 ± 1.09 0.816
 HDL-C (mmol/L) 1.07 ± 0.68 1.07 ± 0.71 1.07 ± 0.65 0.951
 LDL-C (mmol/L) 2.40 ± 0.91 2.38 ± 0.85 2.41 ± 0.91 0.314
 TG (mmol/L) 1.62 ± 1.21 1.54 ± 1.40 1.70 ± 0.98 0.000
Medications
 Aspirin, n (%) 3415 (93.79) 1712 (94.17) 1703 (93.42) 0.138
 ACEI, n (%) 1503 (41.28) 720 (39.60) 783 (42.95) 0.530
 β-blocker, n(%) 1821 (50.01) 891 (49.01) 930 (51.01) 0.960
 Statins, n (%) 3442 (94.53) 1725 (94.88) 1717 (94.19) 0.153
CAD classification     
 SAP 899 (24.69) 486 (26.73) 413 (22.65) 0.950
 ACS 2742 (75.3) 1128 (62.05) 1614 (88.54) 0.030